Eton Pharmaceuticals (ETON) Stock Price

Eton Pharmaceuticals Price

NASDAQ·CLOSED
61.03USD+2.17 (+3.62 %)
Market closed

Over the last 6 years Eton Pharmaceuticals grew revenue by 109.0% annually, reaching 79.95 M USD. For Eton Pharmaceuticals, the net margin of -5.8% is up versus -9.0% a few years ago. The consensus 12-month price target for Eton Pharmaceuticals is 29.58 USD, about 51.5% below where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 325% above its 52-week low.

Eton Pharmaceuticals stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Eton Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Eton Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Eton Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Eton Pharmaceuticals Stock Price History
DateEton Pharmaceuticals Price
8/18/202661.03 USD
8/14/202658.86 USD
8/13/202640.80 USD
8/12/202642.65 USD
8/10/202643.67 USD
8/7/202644.60 USD
8/6/202646.18 USD
8/5/202645.78 USD
8/4/202645.52 USD
8/3/202645.14 USD
7/31/202646.42 USD
7/30/202649.03 USD
7/29/202647.31 USD
7/27/202642.85 USD
7/23/202644.14 USD
7/22/202643.58 USD
7/21/202643.20 USD
7/20/202641.07 USD
7/17/202642.32 USD
7/16/202637.19 USD
7/15/202638.50 USD
7/14/202637.51 USD
7/13/202636.60 USD
7/10/202636.61 USD
7/9/202637.33 USD
7/8/202637.06 USD
7/7/202637.74 USD
7/6/202637.75 USD
7/2/202637.50 USD
7/1/202636.63 USD
6/30/202636.20 USD
6/29/202636.73 USD
6/26/202635.70 USD
6/25/202634.82 USD
6/24/202633.98 USD
6/23/202633.49 USD
6/22/202632.02 USD
6/18/202632.35 USD
6/17/202632.27 USD
6/16/202632.36 USD
6/15/202631.62 USD
6/12/202631.95 USD
6/11/202632.40 USD
6/10/202630.77 USD
6/9/202630.53 USD
6/8/202629.95 USD
6/5/202629.13 USD
6/4/202628.90 USD
6/3/202627.61 USD
6/2/202627.40 USD
6/1/202628.68 USD
5/29/202630.45 USD
5/28/202631.86 USD
5/27/202632.40 USD
5/26/202631.29 USD
5/22/202632.59 USD
5/21/202635.00 USD
5/20/202634.45 USD
5/19/202632.89 USD
5/18/202632.49 USD
5/15/202630.26 USD
5/14/202629.96 USD
5/13/202630.82 USD
5/12/202629.71 USD
5/11/202629.84 USD
5/8/202629.65 USD
5/7/202631.02 USD
5/6/202630.15 USD
5/5/202630.38 USD
5/4/202630.16 USD
5/1/202628.90 USD
4/30/202624.12 USD
4/29/202623.58 USD
4/28/202624.16 USD
4/27/202623.45 USD
4/24/202623.02 USD
4/23/202623.28 USD
4/22/202623.61 USD
4/21/202623.54 USD
4/20/202625.28 USD
4/17/202625.04 USD
4/16/202624.43 USD
4/15/202626.97 USD
4/14/202627.12 USD
4/13/202626.05 USD
4/10/202626.36 USD
4/9/202627.10 USD
4/8/202626.40 USD
4/7/202625.06 USD
4/6/202625.00 USD
4/2/202624.99 USD
4/1/202625.36 USD
3/31/202624.68 USD
3/30/202622.58 USD
3/27/202623.24 USD
3/26/202623.45 USD
3/25/202623.84 USD
3/24/202622.97 USD
3/23/202623.81 USD
3/20/202622.32 USD
3/19/202620.77 USD
3/18/202619.02 USD
3/17/202618.92 USD
3/16/202619.01 USD
3/13/202618.93 USD
3/12/202619.02 USD
3/11/202618.09 USD
3/10/202617.40 USD
3/9/202616.70 USD
3/6/202616.80 USD
3/5/202617.24 USD
3/4/202617.53 USD
3/3/202617.45 USD
3/2/202618.15 USD
2/27/202616.99 USD
2/26/202617.25 USD
2/25/202617.65 USD
2/24/202618.28 USD
2/23/202618.28 USD
2/20/202617.93 USD
2/19/202618.22 USD
2/18/202617.21 USD
2/17/202617.15 USD
2/13/202617.07 USD
2/12/202616.79 USD
2/11/202616.05 USD
2/10/202615.21 USD
2/9/202614.81 USD
2/6/202614.76 USD
2/5/202614.35 USD
2/4/202614.75 USD
2/3/202615.39 USD
2/2/202615.17 USD
1/30/202615.01 USD
1/29/202615.25 USD
1/28/202614.76 USD
1/27/202615.04 USD
1/26/202615.11 USD
1/23/202614.99 USD
1/22/202615.27 USD
1/21/202615.17 USD
1/20/202615.36 USD
1/16/202615.14 USD
1/15/202615.41 USD
1/14/202615.67 USD
1/13/202615.73 USD
1/12/202615.47 USD
1/9/202615.46 USD
1/8/202616.52 USD
1/7/202616.51 USD
1/6/202616.57 USD
1/5/202616.73 USD
1/2/202616.26 USD
12/31/202516.91 USD
12/30/202516.79 USD
12/29/202516.80 USD
12/26/202516.83 USD
12/24/202516.99 USD
12/23/202516.55 USD
12/22/202516.57 USD
12/19/202516.37 USD
12/18/202516.02 USD
12/17/202515.82 USD
12/16/202515.95 USD
12/15/202515.95 USD
12/12/202516.70 USD
12/11/202516.88 USD
12/10/202516.41 USD
12/9/202516.36 USD
12/8/202516.36 USD
12/5/202516.26 USD
12/4/202516.81 USD
12/3/202516.50 USD
12/2/202515.37 USD
12/1/202515.45 USD
11/28/202516.15 USD
11/26/202516.19 USD
11/25/202516.28 USD
11/24/202515.85 USD
11/21/202516.46 USD
11/20/202516.30 USD
11/19/202516.82 USD
11/18/202517.20 USD
11/17/202517.26 USD
11/14/202516.94 USD
11/13/202516.88 USD
11/12/202517.46 USD
11/11/202517.66 USD
11/10/202516.92 USD
11/7/202516.90 USD
11/6/202519.14 USD
11/5/202519.25 USD
11/4/202518.45 USD
11/3/202517.96 USD
10/31/202518.01 USD
10/30/202518.25 USD
10/29/202518.31 USD
10/28/202518.60 USD
10/27/202518.48 USD
10/24/202518.46 USD
10/23/202518.54 USD
10/22/202518.66 USD
10/21/202518.55 USD
10/20/202518.40 USD
10/17/202518.18 USD
10/16/202518.34 USD
10/15/202519.15 USD
10/14/202518.77 USD
10/13/202518.08 USD
10/10/202519.66 USD
10/9/202520.28 USD
10/8/202520.93 USD
10/7/202521.15 USD
10/6/202520.73 USD
10/3/202519.93 USD
10/2/202519.80 USD
10/1/202520.26 USD
9/30/202521.73 USD
9/29/202522.48 USD
9/26/202521.27 USD
9/25/202520.14 USD
9/24/202519.93 USD
9/23/202519.83 USD
9/22/202518.37 USD
9/19/202518.34 USD
9/18/202518.46 USD
9/17/202517.68 USD
9/16/202517.56 USD
9/15/202517.78 USD
9/12/202517.65 USD
9/11/202517.57 USD
9/10/202517.42 USD
9/9/202517.85 USD
9/8/202517.78 USD
9/5/202517.67 USD
9/4/202517.87 USD
9/3/202517.45 USD
9/2/202517.19 USD
8/29/202517.31 USD
8/28/202517.28 USD
8/27/202517.28 USD
8/26/202517.46 USD
8/25/202517.09 USD
8/22/202517.30 USD
8/21/202517.09 USD
8/20/202516.55 USD
8/19/202516.20 USD
Access this data via the Eulerpool API
Get Free API Key

Eton Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
31.64 M USD
-1.19 M USD
-936,000.00 USD
Jan 1, 2024
39.01 M USD
-2.60 M USD
-3.82 M USD
Jan 1, 2025
79.95 M USD
72,000.00 USD
-4.60 M USD
Jan 1, 2026 (e)
149.70 M USD
-13.35 M USD
37.55 M USD
Jan 1, 2027 (e)
219.91 M USD
-21.36 M USD
69.20 M USD
Jan 1, 2028 (e)
245.53 M USD
-28.44 M USD
82.34 M USD
Jan 1, 2029 (e)
340.13 M USD
-39.40 M USD
127.40 M USD
Jan 1, 2030 (e)
426.00 M USD
-49.35 M USD
168.52 M USD

Eton Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 18, 2026, 11:35 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
––––21.0021.0031.0039.0079.00149.00219.00245.00340.00426.00
––––––47.6225.81102.5688.6146.9811.8738.7825.29
––––90.4866.6767.7458.9753.1653.1653.1653.1653.1653.16
42.0042.0042.0042.0019.0014.0021.0023.0042.0079.22116.43130.25180.76226.48
-7.00-10.00-18.00-27.00-1.00-9.00-1.00-2.00–-13.00-21.00-28.00-39.00-49.00
––––-4.76-42.86-3.23-5.13–-8.72-9.59-11.43-11.47-11.50
-7.00-12.00-18.00-27.00-1.00-9.00–-3.00-4.0037.0069.0082.00127.00168.00
–71.4350.0050.00-96.30800.00––33.33-1,025.0086.4918.8454.8832.28
3.5811.6417.9223.8125.9625.6925.7426.1426.9126.9126.9126.9126.9126.91
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Eton Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Eton Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Eton Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Eton Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Eton Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Eton Pharmaceuticals stock margins

The Eton Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eton Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eton Pharmaceuticals.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
87.99 %
-8.95 %
-8.95 %
Jan 1, 2022
67.38 %
-42.45 %
-42.45 %
Jan 1, 2023
66.56 %
-3.77 %
-2.96 %
Jan 1, 2024
60.01 %
-6.66 %
-9.80 %
Jan 1, 2025
53.46 %
0.09 %
-5.75 %
Jan 1, 2026 (e)
53.46 %
-8.92 %
25.08 %
Jan 1, 2027 (e)
53.46 %
-9.71 %
31.47 %
Jan 1, 2028 (e)
53.46 %
-11.58 %
33.53 %

Eton Pharmaceuticals Stock Revenue, EBIT, Earnings per Share

The Eton Pharmaceuticals earnings per share therefore indicates how much revenue Eton Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.84 USD
-0.08 USD
-0.08 USD
Jan 1, 2022
0.83 USD
-0.35 USD
-0.35 USD
Jan 1, 2023
1.23 USD
-0.05 USD
-0.04 USD
Jan 1, 2024
1.49 USD
-0.10 USD
-0.15 USD
Jan 1, 2025
2.97 USD
0.00 USD
-0.17 USD
Jan 1, 2026 (e)
5.58 USD
-0.50 USD
1.40 USD
Jan 1, 2027 (e)
8.20 USD
-0.79 USD
2.58 USD
Jan 1, 2028 (e)
9.15 USD
-1.06 USD
3.07 USD

Eton Pharmaceuticals business model & stock analysis

The company Eton Pharmaceuticals Inc is an innovative company that specializes in the development of high-quality and reliable medications. The company was founded in 2017 in Deer Park, Illinois, and has since become a leading company in the pharmaceutical industry. Eton Pharmaceuticals Inc's business model is closely related to the development of new medications. The company specializes in the development of so-called "gel-coated" medications, which have better efficacy and tolerability than conventional medications. The company uses innovative and patented technologies to overcome the current limitations of medications and provide customers with the best possible treatment. Eton Pharmaceuticals Inc has different divisions for the development of medications. One of the most important divisions is oncology, where medications for tumor treatment are developed. The company relies on innovative approaches to discover new active substances and improve the treatment of cancer patients. In addition, the company has extensive experience in the production of antibiotics. Eton Pharmaceuticals Inc has developed its own products tailored to the needs of patients, promising fast and effective effects. The company has also developed special medications for the treatment of cardiovascular diseases, aiming to provide patients with a better quality of life. One of the products offered by Eton Pharmaceuticals Inc is the medication "BML-190". This medication is an anti-inflammatory drug used for pain and inflammation. Its special feature is its high effectiveness with minimal side effects, which often occur with other medications. Another product of Eton Pharmaceuticals Inc is the medication "DS-300", used for certain eye diseases. The medication contains an active substance that acts on the eyes and allows for quick healing. Thanks to the innovative technology used in its development, this medication is well tolerated and has minimal side effects. Overall, Eton Pharmaceuticals Inc is an innovative company specializing in the development of high-quality medications. With its business model and expertise in various areas of the pharmaceutical industry, the company is well equipped to continue making significant contributions to healthcare.

Eton Pharmaceuticals SWOT Analysis

Strengths

1. Strong product portfolio comprising a diverse range of pharmaceuticals.

2. Well-established presence in the pharmaceutical industry.

3. Robust distribution network, ensuring wide market reach.

Weaknesses

1. Relatively small market share compared to larger pharmaceutical companies.

2. Limited financial resources for research and development.

3. Vulnerability to changes in regulatory environment and pricing pressures.

Opportunities

1. Potential for expansion into emerging markets with increasing healthcare needs.

2. Growing demand for specialized pharmaceuticals targeting specific medical conditions.

3. Collaborations and partnerships with other pharmaceutical companies for joint product development.

Threats

1. Intense competition from larger pharmaceutical companies with greater resources.

2. Regulatory challenges and stringent approval processes for new drug releases.

3. Fluctuations in healthcare policies and reimbursement systems impacting pricing and market access.

Eton Pharmaceuticals Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Eton Pharmaceuticals Employees
Details
Date
Eton Pharmaceuticals Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Eton Pharmaceuticals Segments

Eton Pharmaceuticals Revenue by Segment (1/4)

  • 3 Years

  • 5 Years

  • Max

Licensing Revenue
License
Product
Product Sales
Product Sales, Net
Details
Date
Licensing Revenue
License
Product
Product Sales
Product Sales, Net
Jan 1, 2019
500,000.00 USD
0.00 USD
0.00 USD
459,000.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
39,000.00 USD
Jan 1, 2021
19.00 M USD
0.00 USD
2.83 M USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
3.29 M USD
0.00 USD
0.00 USD
0.00 USD

Eton Pharmaceuticals Revenue by Segment (2/4)

  • Max

License
Details
Date
License
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2024
500,000.00 USD
Jan 1, 2025
0.00 USD

Eton Pharmaceuticals Revenue by Segment (3/4)

  • Max

Product Sales and Royalties
Details
Date
Product Sales and Royalties
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2024
38.51 M USD
Jan 1, 2025
0.00 USD

Eton Pharmaceuticals Revenue by Segment (4/4)

  • Max

Product Sales and Royalties
Details
Date
Product Sales and Royalties
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
76.66 M USD

Eton Pharmaceuticals Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Eton Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Eton Pharmaceuticals annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Eton Pharmaceuticals shares outstanding

The number of shares of Eton Pharmaceuticals was 26.91 M in 2025. This indicates how many shares Eton Pharmaceuticals is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
25.96 M Stocks
Jan 1, 2022
25.69 M Stocks
Jan 1, 2023
25.74 M Stocks
Jan 1, 2024
26.14 M Stocks
Jan 1, 2025
26.91 M Stocks
Jan 1, 2026 (e)
26.91 M Stocks
Jan 1, 2027 (e)
26.91 M Stocks
Jan 1, 2028 (e)
26.91 M Stocks

Current Eton Pharmaceuticals forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
29.58
Last Price
58.86
Currency
USD
12M Return Potential
-49.75 %
LTM Return
0 %

Eton Pharmaceuticals Analyst Rating Actions

DateFirmActionRating
7/28/2026
Craig-Hallum
Craig-Hallum
MaintainedBuy
5/15/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
3/20/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
3/20/2026
Craig-Hallum
Craig-Hallum
MaintainedBuy
3/20/2026
B. Riley Securities
B. Riley Securities
MaintainedBuy
3/3/2026
Craig-Hallum
Craig-Hallum
MaintainedBuy
3/2/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
5/29/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
5/16/2025
B. Riley Securities
B. Riley Securities
MaintainedBuy
5/14/2025
Craig-Hallum
Craig-Hallum
MaintainedBuy

Eton Pharmaceuticals Earnings Calls

2025

Eton Pharmaceuticals Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/13/20260.12USD-27.66 MUSD-2026 Q2
5/14/20260.09USD-22.76 MUSD-2026 Q1
3/19/20260.09USD-20.99 MUSD-2025 Q4
11/14/2024-0.01USD-9.89 MUSD-2024 Q3
3/6/2023-0.01USD-9.12 MUSD-2022 Q4
11/10/2022-0.15USD-3.09 MUSD-2022 Q3
8/11/20220.03USD-7.88 MUSD-2022 Q2
5/12/2022-0.08USD-7.21 MUSD-2022 Q1
3/16/20220.19USD-12.71 MUSD-2021 Q4
11/15/2021-0.14USD-3.09 MUSD-2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Eton Pharmaceuticals stock

23/100
23
Environment
37
Social
8
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Eton Pharmaceuticals shareholder structure

% Name
10.66368%
Opaleye Management Inc.
Opaleye Management Inc.
7.57101%
EcoR1 Capital, LLC
EcoR1 Capital, LLC
5.21809%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
5.01161%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.38460%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
2.21053%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
...

Eton Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)

Free Float
76.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
20.70%
Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals, Inc.
SEC ↗
11.00%
Oleg Nodelman
Oleg Nodelman
SEC ↗
11.00%
EcoR1 Capital Fund Qualified, L.P.
EcoR1 Capital Fund Qualified, L.P.
SEC ↗
11.00%
Opaleye Management Inc.
Opaleye Management Inc.
SEC ↗
11.00%
1
1
SEC ↗
10.34%
Private Capital Management, LLC (46-3167283)
Private Capital Management, LLC (46-3167283)
SEC ↗
9.69%
20-5648796
20-5648796
SEC ↗
7.70%
EcoR1 Capital, LLC
EcoR1 Capital, LLC
SEC ↗
7.60%
Brynjelsen
Brynjelsen
SEC ↗
6.66%
BARCLAYS GLOBAL INVESTORS, NA.
BARCLAYS GLOBAL INVESTORS, NA.
SEC ↗

Eton Pharmaceuticals Executives and Management Board

8 members · avg. age 58 · 25 % women

SB

Mr. Sean Brynjelsen (53)

President, Chief Executive Officer, Director · since 2017

2.41 M USD

Management

DK

Mr. David Krempa (36)

Chief Business Officer

1.33 M USD
JG

Mr. James Gruber (53)

Chief Financial Officer, Treasurer, Secretary

1.08 M USD
IE

Ms. Ipek Erdogan-Trinkaus (43)

Chief Commercial Officer

775,488.00 USD

Board of Directors

NR

Dr. Norbert Riedel (67)

Independent Chairman of the Board

188,586.00 USD
PM

Mr. Paul Maier (77)

Independent Director

161,546.00 USD
CC

Mr. Charles Casamento (79)

Independent Director

158,842.00 USD
JA

Ms. Jennifer Adams (56)

Independent Director

150,730.00 USD

Eton Pharmaceuticals Supply Chain

Eton Pharmaceuticals Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#NameTrend
1
Diurnal Group
Supplier·Customer·Biotechnology·GB
-0.68
0.77
0.32
0.30
0.57
0.47
#NameTrend
1
AmerisourceBergen
Customer·Health Care Providers & Services·US
0.24
0.04
0.07
-0.21
-0.68
-0.74
2
McKesson
Customer·Health Care Providers & Services·US
0.43
-0.48
-0.42
-0.35
-0.76
-0.73
3
Harrow Health
Supplier·Customer·Pharmaceuticals·US
0.27
0.77
0.76
0.53
0.62
-0.16
4
Cardinal Health
Customer·Health Care Providers & Services·US
0.72
0.91
0.14
-0.10
-0.05
0.05
5
Bausch Health
Supplier·Customer·CA
-0.17
0.90
0.90
0.76
0.73
0.12

Frequently asked questions about Eton Pharmaceuticals

Eton Pharmaceuticals Inc has achieved several significant milestones. The company successfully received approval from the U.S. Food and Drug Administration (FDA) for multiple Abbreviated New Drug Applications (ANDAs). This includes the approval of important medications such as Topiramate Oral Solution and Levetiracetam Oral Solution. Eton Pharmaceuticals Inc has also entered into strategic partnerships and collaborations to further enhance its product portfolio and expand its market reach. These milestones highlight Eton Pharmaceuticals Inc's commitment to advancing the development and commercialization of high-quality pharmaceutical products.

The business model of Eton Pharmaceuticals Inc revolves around developing and commercializing innovative and cost-effective drug products. Eton Pharmaceuticals focuses on improving the therapeutic availability of currently approved drugs through formulation enhancements. They aim to address unmet medical needs by developing and marketing high-quality generic pharmaceuticals for both branded and non-branded markets. Eton Pharmaceuticals utilizes a strategic combination of in-house research and development, acquisitions, collaborations, and licensing agreements to expand their product portfolio. By implementing their unique business model, Eton Pharmaceuticals Inc strives to provide affordable and accessible treatments to patients in need.

Eton Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The main competitors of Eton Pharmaceuticals Inc in the market include various pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, GlaxoSmithKline, and Eli Lilly.

Eton Pharmaceuticals Inc is a pharmaceutical company based in Deer Park, Illinois, United States. Established in 2017, Eton Pharmaceuticals focuses on developing and marketing innovative drug products primarily in the United States. The company aims to address unmet medical needs, enhance patient accessibility, and improve medication delivery options. Eton Pharmaceuticals leverages its expertise in drug formulation and regulatory activities to create high-quality, affordable, and safe medications. With a strong commitment to improving patient care, Eton Pharmaceuticals continuously seeks opportunities to expand its product portfolio and contribute to advancing healthcare.

Eton Pharmaceuticals Inc is primarily present in the United States.

Eton Pharmaceuticals Inc represents core values of innovation, quality, and patient care. The company is committed to delivering high-quality and innovative pharmaceutical products that meet the needs of patients and healthcare professionals. Eton Pharmaceuticals Inc embraces a patient-centric approach and aims to improve health outcomes by providing accessible and affordable medications. With a strong focus on research and development, Eton Pharmaceuticals Inc continuously strives to bring new and effective treatments to the market. The company's corporate philosophy revolves around integrity, transparency, and ethical business practices, ensuring trust and confidence among its stakeholders.

Analysts currently set an average price target of 30.60 USD for the Eton Pharmaceuticals stock (median: 29.58 USD), implying -48.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Eton Pharmaceuticals Analyst Price Targets 2026

9 analysts currently rate the Eton Pharmaceuticals stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Eton Pharmaceuticals to generate revenue of 149.70 M USD and earnings per share of 1.40 USD.

Eton Pharmaceuticals Analyst Price Targets 2026

Converted at the current exchange rate, the Eton Pharmaceuticals share trades at 52.67 EUR (61.03 USD).

The Eton Pharmaceuticals share (ETON) is listed on 1 stock exchanges, including: NASDAQ (ETON).

Eton Pharmaceuticals Inc is a leading company in the pharmaceutical industry that focuses on the development and marketing of prescription drugs. The company's business model is based on identifying healthcare needs and developing innovative solutions for those needs. Eton Pharmaceuticals Inc is divided into several business areas, including drug development, manufacturing, registration, and marketing of medications. Drug development Eton Pharmaceuticals Inc heavily invests in research and development to develop high-quality and innovative medications for various diseases. The company specializes in developing drugs for rare diseases and diseases for which there is no effective treatment option yet. The company has a comprehensive portfolio of patented technologies and active ingredients used in drug manufacturing. Manufacturing Eton Pharmaceuticals Inc operates its own production facility for manufacturing active ingredients and medications. Manufacturing is done according to the highest quality standards and compliance with applicable regulations. The production facility is capable of producing both small and large quantities of medications to meet customer needs. Manufacturing is conducted under strict quality control and Good Manufacturing Practice (GMP) guidelines. Registration Eton Pharmaceuticals Inc possesses comprehensive knowledge of regulatory requirements and regulations in the pharmaceutical industry. The company utilizes this knowledge to manufacture safe and effective medications that meet the strict requirements of regulatory authorities. Eton Pharmaceuticals Inc works closely with authorities to achieve and implement medication approvals. Marketing Eton Pharmaceuticals Inc markets its products in the national and international market. The company works closely with distributors, wholesalers, pharmacies, and hospitals to distribute the products. Eton Pharmaceuticals Inc utilizes effective marketing strategies to create awareness for its products. The company employs a distribution channel strategy to achieve a broader reach. Products Eton Pharmaceuticals Inc offers a wide range of prescription medications for various diseases. This includes medications for rare diseases, colds, allergies, asthma, and other diseases for which there is no effective treatment option yet. Products like Alkindi Sprinkle, a medication for pediatric adrenal insufficiency, have already received US approval. Summary The business model of Eton Pharmaceuticals Inc is based on the development and marketing of high-quality and innovative prescription medications. The company has built comprehensive expertise in all areas of the pharmaceutical industry to deliver effective solutions for healthcare needs. The company pursues effective business strategies to enhance competitiveness and promote corporate growth.

The expected revenue of Eton Pharmaceuticals is 149.70 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Eton Pharmaceuticals is 37.55 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Eton Pharmaceuticals is currently 43.73. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Eton Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Eton Pharmaceuticals is currently 10.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Eton Pharmaceuticals stock.

The Eulerpool Quality Score for Eton Pharmaceuticals is 4/10.

The ISIN of Eton Pharmaceuticals is US29772L1089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Eton Pharmaceuticals is A2N38G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Eton Pharmaceuticals is ETON. The ticker symbol is used to trade Eton Pharmaceuticals shares on the stock exchange.

Eton Pharmaceuticals paid dividends every year for the past 0 years.

Eton Pharmaceuticals is assigned to the 'Health' sector.

The dividends of Eton Pharmaceuticals are distributed in USD.

All fundamentals and in-depth analysis of Eton Pharmaceuticals

Our stock analysis for Eton Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eton Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Eton Pharmaceuticals Stock
Eton Pharmaceuticals Revenue→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Net Income→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals P/E→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals P/S→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals EBIT→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Dividend→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Directors Dealings→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Stocks→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Market capitalization→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Debt→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Liabilities→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Equity→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals AAQS→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Employees→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals ROE→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals ROA→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals ROCE→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals News→
Eton Pharmaceuticals Stock
Eton Pharmaceuticals Analyst Price Targets→

Health Stocks

EuBiologics CoEthk LabsEUDA Health HoldingsEthema HealthEukedos SpAETAO International CoEuro-Med Laboratories PhilEstrella ImmunopharmaEuroapiEstablishment Labs HoldingsEurobio ScientificEssex Bio-TechnologyAll Stocks A–Z →